Given that the frequency of SLC26A4 mutations in Korean patients with EVA is >90%, it is reasonable to perform TBCT for discriminating between patients with hearing loss due to SLC26A4 mutations and those with NSHL due to other AR mutations9. Here, SLC26A4 is linked to nodular sclerosis classical Hodgkin lymphoma.